Bafna Pharmaceuticals (BAFNAPH) Q2 26/27 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 26/27 earnings summary
11 Nov, 2026Executive summary
Board approved unaudited Q2 and H1 results for the period ended September 30, 2026; statutory auditors completed a limited review.
Financial highlights
Q2 revenue from operations was INR 4,766.56 lakh vs INR 3,546.82 lakh YoY; H1 revenue was INR 7,424.88 lakh vs INR 7,009.22 lakh.
Q2 profit for the period was INR 684.82 lakh vs INR 312.49 lakh YoY; H1 profit was INR 692.33 lakh vs INR 651.38 lakh.
H1 total income was INR 7,729.39 lakh vs INR 7,186.75 lakh; total expenses were INR 7,037.06 lakh vs INR 6,535.37 lakh.
Segment performance
Pharmaceutical formulations manufacturing is the sole operating segment under Ind AS 108.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Bafna Pharmaceuticals
- Q1 FY27 saw sharp declines in revenue and profit, with GST disputes not impacting outlook.BAFNAPH
Q1 26/27 - FY26 net profit more than doubled year-over-year, with strong revenue growth and clean audit.BAFNAPHQ4 25/26
- Quarterly revenue and profit increased year-over-year, with key tax and GST risks under appeal.BAFNAPHQ3 2026
- Q2 FY26 profit increased to ₹312.49 lakhs, with revenue at ₹3,546.82 lakhs and higher EPS.BAFNAPHQ2 25/26
- Returned to profitability with higher revenue and completed key asset sale in the quarter.BAFNAPHQ1 25/26
- Q2 FY25 saw higher revenue and profit, but compliance and receivable risks persist.BAFNAPHQ2 24/25
- Q1 FY25 posted a net loss and lower revenue, with compliance and receivable risks highlighted.BAFNAPHQ1 24/25
- Net profit fell despite higher revenue, with key assets held for sale and compliance milestones met.BAFNAPHQ4 24/25
- Q3 FY25 marked a return to profitability with higher revenue and no outstanding debt.BAFNAPHQ3 2025